Cargando…
Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder
Objectives: To investigate child and parental characteristics of medication use for attention-deficit/hyperactivity disorder (ADHD). Methods: Participants were part of the prospective population-based Norwegian Mother, Father and Child Cohort study (MoBa) (n = 114,500 children, 95,000 mothers, and 7...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475088/ https://www.ncbi.nlm.nih.gov/pubmed/32672488 http://dx.doi.org/10.1089/cap.2019.0019 |
_version_ | 1783579448817221632 |
---|---|
author | Oerbeck, Beate Furu, Kari Zeiner, Pal Aase, Heidi Reichborn-Kjennerud, Ted Pripp, Are Hugo Overgaard, Kristin Romvig |
author_facet | Oerbeck, Beate Furu, Kari Zeiner, Pal Aase, Heidi Reichborn-Kjennerud, Ted Pripp, Are Hugo Overgaard, Kristin Romvig |
author_sort | Oerbeck, Beate |
collection | PubMed |
description | Objectives: To investigate child and parental characteristics of medication use for attention-deficit/hyperactivity disorder (ADHD). Methods: Participants were part of the prospective population-based Norwegian Mother, Father and Child Cohort study (MoBa) (n = 114,500 children, 95,000 mothers, and 75,000 fathers). This cohort was linked to the Norwegian Prescription Database (NorPD) and the Norwegian Patient Registry (NPR) to compare child and parental characteristics in children medicated and not medicated for ADHD during years 2008–2013. Results: One thousand seven hundred and sixty-four children (74% boys) with ADHD (International Classification of Diseases [ICD-10]: F90 and F98.8) were identified. One thousand three hundred and sixty-two (77%) used medication. Boys and girls did not differ in the use of ADHD medication (both 77%). Mean age at first prescription was 9 years in both boys and girls, and age at ADHD diagnosis was 8 years in medicated and unmedicated children. Significantly more hyperkinetic conduct disorders (F90.1), and significantly fewer with attention-deficit disorder (F98.8) were found among the medicated children compared to the unmedicated children. The medicated children also had a significantly lower global functioning (Child Global Assessment Scale). Child disruptive symptoms reported in the MoBa child age 3 year questionnaire were significantly higher in children who used medication compared to the nonusers (t = 2.2, p = 0.03), and group differences in ADHD symptoms at age 3 years were close to significant (t = 1.8, p = 0.07). Other preschool child and parental characteristics were not significantly different in the two groups. Conclusion: In this large birth cohort study, where a great majority of children with ADHD used medication, only child characteristics were significantly associated with the use of medication. We could not replicate previous findings suggesting that “environmental factors,” such as parental education and psychopathology, drive medication use. The small differences between medicated and unmedicated children in this cohort study, where a majority used medication, might be due to strong established clinical practices where medication is offered as a treatment option, particularly for hyperkinetic conduct disorder in an egalitarian high-income society. |
format | Online Article Text |
id | pubmed-7475088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-74750882020-09-08 Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder Oerbeck, Beate Furu, Kari Zeiner, Pal Aase, Heidi Reichborn-Kjennerud, Ted Pripp, Are Hugo Overgaard, Kristin Romvig J Child Adolesc Psychopharmacol Original Articles Objectives: To investigate child and parental characteristics of medication use for attention-deficit/hyperactivity disorder (ADHD). Methods: Participants were part of the prospective population-based Norwegian Mother, Father and Child Cohort study (MoBa) (n = 114,500 children, 95,000 mothers, and 75,000 fathers). This cohort was linked to the Norwegian Prescription Database (NorPD) and the Norwegian Patient Registry (NPR) to compare child and parental characteristics in children medicated and not medicated for ADHD during years 2008–2013. Results: One thousand seven hundred and sixty-four children (74% boys) with ADHD (International Classification of Diseases [ICD-10]: F90 and F98.8) were identified. One thousand three hundred and sixty-two (77%) used medication. Boys and girls did not differ in the use of ADHD medication (both 77%). Mean age at first prescription was 9 years in both boys and girls, and age at ADHD diagnosis was 8 years in medicated and unmedicated children. Significantly more hyperkinetic conduct disorders (F90.1), and significantly fewer with attention-deficit disorder (F98.8) were found among the medicated children compared to the unmedicated children. The medicated children also had a significantly lower global functioning (Child Global Assessment Scale). Child disruptive symptoms reported in the MoBa child age 3 year questionnaire were significantly higher in children who used medication compared to the nonusers (t = 2.2, p = 0.03), and group differences in ADHD symptoms at age 3 years were close to significant (t = 1.8, p = 0.07). Other preschool child and parental characteristics were not significantly different in the two groups. Conclusion: In this large birth cohort study, where a great majority of children with ADHD used medication, only child characteristics were significantly associated with the use of medication. We could not replicate previous findings suggesting that “environmental factors,” such as parental education and psychopathology, drive medication use. The small differences between medicated and unmedicated children in this cohort study, where a majority used medication, might be due to strong established clinical practices where medication is offered as a treatment option, particularly for hyperkinetic conduct disorder in an egalitarian high-income society. Mary Ann Liebert, Inc., publishers 2020-09-01 2020-08-28 /pmc/articles/PMC7475088/ /pubmed/32672488 http://dx.doi.org/10.1089/cap.2019.0019 Text en © Beate Oerbeck et al. 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited. |
spellingShingle | Original Articles Oerbeck, Beate Furu, Kari Zeiner, Pal Aase, Heidi Reichborn-Kjennerud, Ted Pripp, Are Hugo Overgaard, Kristin Romvig Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder |
title | Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder |
title_full | Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder |
title_fullStr | Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder |
title_full_unstemmed | Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder |
title_short | Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder |
title_sort | child and parental characteristics of medication use for attention-deficit/hyperactivity disorder |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475088/ https://www.ncbi.nlm.nih.gov/pubmed/32672488 http://dx.doi.org/10.1089/cap.2019.0019 |
work_keys_str_mv | AT oerbeckbeate childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder AT furukari childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder AT zeinerpal childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder AT aaseheidi childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder AT reichbornkjennerudted childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder AT pripparehugo childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder AT overgaardkristinromvig childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder |